<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C49C66E3-8EF1-43E8-82A1-7A8347F84C2B"><gtr:id>C49C66E3-8EF1-43E8-82A1-7A8347F84C2B</gtr:id><gtr:name>Sentinel Oncology Limited</gtr:name><gtr:address><gtr:line1>SUITE 52 23 SCIENCE PARK , MILTON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C49C66E3-8EF1-43E8-82A1-7A8347F84C2B" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>C49C66E3-8EF1-43E8-82A1-7A8347F84C2B</gtr:id><gtr:name>Sentinel Oncology Limited</gtr:name><gtr:address><gtr:line1>SUITE 52 23 SCIENCE PARK , MILTON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>136431.0</gtr:offerGrant><gtr:projectCost>194901.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=133051"><gtr:id>F472C497-966B-4228-994A-710A0D37E8CF</gtr:id><gtr:title>Validating a New Therapeutic Opportunity for the Treatment of Alzheimer?s Disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>133051</gtr:grantReference><gtr:abstractText>There are no effective treatments for Alzheimer?s disease. The incidence and health care costs of treating dementia are set to increase in the coming decades and there is an overwhelming need for effective treatments. Sentinel Oncology Limited (SOL) has developed a new class of drug molecules that have the potential to treat Alzheimer?s Disease. These new drugs would work by preventing the production and activation of proteins in the brain that are involved with the progression of the disease. The purpose of this project is to carry out proof-of-concept experiments to confirm if the SOL drugs have the potential to treat patients with Alzheimer?s Disease.</gtr:abstractText><gtr:fund><gtr:end>2018-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>136431</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">133051</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>